Cartilage Tissue Engineering by Extrusion Bioprinting: Process Analysis, Risk Evaluation, and Mitigation Strategies.

FMEA/FMECA bioprinting cartilage regeneration translational research

Journal

Materials (Basel, Switzerland)
ISSN: 1996-1944
Titre abrégé: Materials (Basel)
Pays: Switzerland
ID NLM: 101555929

Informations de publication

Date de publication:
24 Jun 2021
Historique:
received: 31 05 2021
revised: 16 06 2021
accepted: 21 06 2021
entrez: 2 7 2021
pubmed: 3 7 2021
medline: 3 7 2021
Statut: epublish

Résumé

Extrusion bioprinting is considered promising in cartilage tissue engineering since it allows the fabrication of complex, customized, and living constructs potentially suitable for clinical applications. However, clinical translation is often complicated by the variability and unknown/unsolved issues related to this technology. The aim of this study was to perform a risk analysis on a research process, consisting in the bioprinting of a stem cell-laden collagen bioink to fabricate constructs with cartilage-like properties. The method utilized was the Failure Mode and Effect Analysis/Failure Mode and Effect Criticality Analysis (FMEA/FMECA) which foresees a mapping of the process to proactively identify related risks and the mitigation actions. This proactive risk analysis allowed the identification of forty-seven possible failure modes, deriving from seventy-one potential causes. Twenty-four failure modes displayed a high-risk level according to the selected evaluation criteria and threshold (RPN > 100). The results highlighted that the main process risks are a relatively low fidelity of the fabricated structures, unsuitable parameters/material properties, the death of encapsulated cells due to the shear stress generated along the nozzle by mechanical extrusion, and possible biological contamination phenomena. The main mitigation actions involved personnel training and the implementation of dedicated procedures, system calibration, printing conditions check, and, most importantly, a thorough knowledge of selected biomaterial and cell properties that could be built either through the provided data/scientific literature or their preliminary assessment through dedicated experimental optimization phase. To conclude, highlighting issues in the early research phase and putting in place all the required actions to mitigate risks will make easier to develop a standardized process to be quickly translated to clinical use.

Identifiants

pubmed: 34202765
pii: ma14133528
doi: 10.3390/ma14133528
pmc: PMC8269498
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Italian Ministry of Health, 5x1000 funds, anno 2017, redditi 2106,
ID : "Sviluppo di un device stampato in 3D per l'inserzione tibiale del legamento crociato anteriore"

Références

Eur Spine J. 2008 Dec;17 Suppl 4:467-79
pubmed: 19005702
Drug Des Devel Ther. 2017 Oct 19;11:3035-3043
pubmed: 29089745
J Biomed Mater Res B Appl Biomater. 2004 Nov 15;71(2):343-54
pubmed: 15386396
J Orthop Sports Phys Ther. 2006 Oct;36(10):717-27
pubmed: 17063834
Acta Biomater. 2018 Jan;65:1-20
pubmed: 29128537
J Mater Sci Mater Med. 2019 Mar 6;30(3):32
pubmed: 30840132
Stem Cells. 2017 Jan;35(1):256-264
pubmed: 27507787
Ann Phys Rehabil Med. 2016 Jun;59(3):139-144
pubmed: 27079583
J Pharm Biomed Anal. 2009 Dec 5;50(5):1085-7
pubmed: 19640668
Tissue Eng Part B Rev. 2014 Dec;20(6):683-96
pubmed: 24923709
Bone Joint Res. 2013 Sep 16;2(9):193-9
pubmed: 24043640
Wound Repair Regen. 2014 May;22 Suppl 1:30-8
pubmed: 24813362
J Orthop Trauma. 2019 Jun;33 Suppl 6:S6-S12
pubmed: 31083142
Int J Biol Macromol. 2018 Apr 15;110:497-503
pubmed: 29054525
Molecules. 2016 Sep 08;21(9):
pubmed: 27617991
PDA J Pharm Sci Technol. 2011 Sep-Oct;65(5):506-12
pubmed: 22293839
Bone Joint Res. 2019 Mar 2;8(2):101-106
pubmed: 30915216
J Mater Chem B. 2018 Dec 7;6(45):7543-7555
pubmed: 32254756
Biotechnol J. 2020 Dec;15(12):e2000095
pubmed: 32869529
Mater Sci Eng C Mater Biol Appl. 2017 Sep 1;78:1246-1262
pubmed: 28575964
Bone. 2015 Jan;70:48-54
pubmed: 25026496
Cochrane Database Syst Rev. 2016 Sep 03;9:CD010675
pubmed: 27590275
Tissue Eng Part B Rev. 2019 Aug;25(4):357-373
pubmed: 30913997
Adv Healthc Mater. 2017 Nov;6(22):
pubmed: 28804984
Bioengineering (Basel). 2020 Jul 01;7(3):
pubmed: 32630194
Int J Bioprint. 2020 Apr 21;6(3):270
pubmed: 33088985
Biofabrication. 2019 Nov 06;12(1):015007
pubmed: 31509811
Tissue Eng Part C Methods. 2019 Jun;25(6):334-343
pubmed: 31007132
J Toxicol Environ Health A. 2019;82(16):891-912
pubmed: 31545145
Clin Chim Acta. 2009 Jun;404(1):75-8
pubmed: 19298799
Tissue Eng Part A. 2020 Mar;26(5-6):358-370
pubmed: 32085691
Materials (Basel). 2018 Sep 17;11(9):
pubmed: 30227656

Auteurs

Mauro Petretta (M)

RegenHU Ltd., Z.I. du Vivier 22, 1690 Villaz-ST-Pierre, Switzerland.
Rizzoli RIT-Research, Innovation & Technology Department, IRCCS Istituto Ortopedico Rizzoli, SSD RAMSES, Via di Barbiano 1/10, 40136 Bologna, Italy.

Giovanna Desando (G)

Rizzoli RIT-Research, Innovation & Technology Department, IRCCS Istituto Ortopedico Rizzoli, SSD RAMSES, Via di Barbiano 1/10, 40136 Bologna, Italy.

Brunella Grigolo (B)

Rizzoli RIT-Research, Innovation & Technology Department, IRCCS Istituto Ortopedico Rizzoli, SSD RAMSES, Via di Barbiano 1/10, 40136 Bologna, Italy.

Livia Roseti (L)

Rizzoli RIT-Research, Innovation & Technology Department, IRCCS Istituto Ortopedico Rizzoli, SSD RAMSES, Via di Barbiano 1/10, 40136 Bologna, Italy.

Classifications MeSH